Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest Melanoma Stories

2014-03-21 12:24:19

The SRT-100(TM) and SRT-100 Vision(TM) are used to treat a host of dermatological and oncological conditions with low-energy radiation therapy BOCA RATON, Fla., March 21, 2014 /PRNewswire/ -- Frost & Sullivan has recognized Sensus Healthcare with the 2014 North American award for New Product Innovation Leadership. Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award...

2014-03-21 08:24:14

ORPINGTON, England, March 21, 2014 /PRNewswire/ -- Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography ('OCT') technology, today announces positive results from the successfully completed multi-centre, prospective clinical trial for the diagnosis of basal cell carcinoma using VivoSight OCT to be presented at the upcoming American Academy of Dermatology's 72nd Annual Meeting (AAD) in Denver, Colorado,...

2014-03-20 12:28:30

The products have demonstrated safety, clinical efficacy, and potential for widespread adoption to treat a host of dermatological and oncological conditions MOUNTAIN VIEW, Calif., March 20, 2014 /PRNewswire/ -- Based on its recent analysis of the non-melanoma skin cancer therapy market, Frost & Sullivan recognizes Sensus Healthcare LLC with the 2014 North American Frost & Sullivan Award for New Product Innovation Leadership. Sensus uses a technique known as superficial radiation...

Cancer Drug Trial Suffers Another Setback
2014-03-20 11:52:30

Lee Rannals for redOrbit.com - Your Universe Online GlaxoSmithKline (GSK) said on Thursday that its cancer drug MAGE-A3 has failed its second test. The company said that the drug missed the first co-primary endpoints during the third phase of its study involving more than 2,000 lung cancer patients. The researchers found that the experimental therapy did not help patients live longer without their disease recurring. During the study, patients were given up to 13 intramuscular...

2014-03-20 08:30:04

The Jeffrey Epstein VI Foundation puts its support behind Congress' largest bill for Melanoma. NEW YORK, March 20, 2014 /PRNewswire/ -- One of Harvard's biggest investors, Jeffrey Epstein, and founder of Harvard's Program for Evolutionary Dynamics, has heralded congress' largest funding bill for melanoma research. The appropriations bill was for the Department of Defense's Peer-Reviewed Cancer Research Program (PRCRP) in the amount of $25 million, and is devoted to research for...

2014-03-17 08:29:07

HOUSTON, March 17, 2014 /PRNewswire-USNewswire/ -- The University of Texas MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate through MD Anderson's Moon Shots Program to develop therapies that unleash patients' immune systems to attack their cancers. "Our collaboration with MedImmune, a leader in the field of immunotherapy, will draw on the strengths of both institutions to push ahead for more effective...

2014-03-14 16:23:20

Data Showed Tumor Shrinkage in Both Injected and Metastasized Tumors THOUSAND OAKS, Calif., March 14, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced findings from a pre-specified retrospective analysis of patients with metastatic melanoma that showed talimogene laherparepvec reduced the size of injected tumors and also non-injected tumors that had metastasized to other parts of the body. The analysis recorded tumor-level responses from a pivotal Phase 3 study evaluating...

2014-03-13 12:25:13

NEW YORK, Feb. 27, 2014 /PRNewswire/ -- Provectus Pharmaceuticals, Inc. (OTC: PVCT) The melanoma version of the drug is the closest to market release. Phase 2 data was finalized in October 2012 and the drug is being prepped for Breakthrough Therapy Designation (BTD) Drug Submission with the FDA and is in the final steps for approval. Once submitted PVCT should receive a decision within 60 days of receipt of that request. The breast and liver cancer versions of the drug have...

2014-03-11 08:31:48

LOS ANGELES, March 11, 2014 /PRNewswire/ -- - Los Angeles dermatologist, Dr. Peyman Ghasri, urges patients to screen their skin and look for skin cancer symptoms. Skin cancer is the most common type of cancer in the world and accounts for about half of all cancers that are diagnosed in the United States. More than 75,000 cases of melanoma and 3.5 million cases of squamous cell and basal cell carcinomas are diagnosed every year.Being aware of skin cancer symptoms can ensure patients...

Scientists Identify Potent Driver Of Metastasis
2014-03-10 12:44:42

The Wistar Institute Protein Correlates with Breast, Bladder, Melanoma, and Thyroid Tumors An international team of researchers led by scientists at The Wistar Institute have discovered and defined LIMD2, a protein that can drive metastasis, the process where tumors spread throughout the body. Their study, published in the March issue of the journal Cancer Research, defines the structure of LIMD2 and correlates the protein in metastatic bladder, melanoma, breast, and thyroid tumors....